

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy:
an individual patient data meta-analysis

Peer-reviewed author version

Sapena, Victor; Enea, Marco; Torres , Ferran; Celsa, Ciro; Rios, Jose; Rizzo, Giacomo Emanuele Maria; Nahon, Pierre; Marino, Zoe; Tateishi, Ryosuke; Minami, Tatsuya; Sangiovanni, Angelo; Forns, Xavier; Toyoda, Hidenori; Brilli, Stefano; Conti, Fabio; Degasper, Elisabetta; Yu, Ming-Lung; Tsai, Pei-Chien; Jean, Kevin; El Kassas, Mohamed; Shousha, Hend Ibrahim; Omar, Ashraf; Zavaglia, Claudio; Nagata, Hiroko; Nakagawa, Mina; Asahina, Yasuhiro; Singal, Amit G.; Murphy, Caitlin; Kohla, Mohamed; Masetti, Chiara; Dufour, Jean-Francois; Merchante, Nicolas; Cavalletto, Luisa; Chemello, Liliana L. C.; Pol, Stanislas; Crespo, Javier; Calleja, Jose Luis; Villani, Rosanna; Serviddio, Gaetano; Zanetto, Alberto; Shalaby, Sarah; Russo, Francesco Paolo; BIELEN, Rob; Trevisani, Franco; Camma, Calogero; Bruix, Jordi; Cabibbo, Giuseppe & Reig, Maria (2022) Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. In: Gut, 71 (3) , p. 593-604.

DOI: 10.1136/gutjnl-2020-323663

Handle: <http://hdl.handle.net/1942/36479>

HEPATOCELLULAR CARCINOMA RECURRENCE AFTER DIRECT-ACTING ANTIVIRAL THERAPY: AN INDIVIDUAL PATIENT DATA META-ANALYSIS.

Víctor Sapena^{1*}, Marco Enea^{2*}, Ferran Torres^{3**}, Ciro Celsa^{2,4**}, Jose Ríos³, Giacomo Emanuele Maria Rizzo², Pierre Nahon⁵, Zoe Mariño⁶, Ryosuke Tateishi⁷, Tatsuya Minami⁷, Angelo Sangiovanni⁸, Xavier Forns⁶, Hidenori Toyoda⁹, Stefano Brillanti¹⁰, Fabio Conti¹⁰, Elisabetta Degasperi⁸, Ming-Lung Yu^{11,12}, Pei-Chien Tsai¹¹, Kevin Jean^{13,14}, Mohamed El Kassas¹⁵, Hend I. Shousha¹⁶, Ashraf O. Abdelaziz¹⁶, Claudio Zavaglia¹⁷, Hiroko Nagata¹⁸, Mina Nakagawa^{18,19}, Yasuhiro Asahina^{18,20}, Amit G. Singal²¹, Caitlin C. Murphy²¹, Mohamed Kohla²², Chiara Masetti²³, Jean-François Dufour^{24,25}, Nicolás Merchante²⁶, Luisa Cavalletto²⁷, Liliana Chemello²⁷, Stanislas Pol²⁸, Javier Crespo²⁹, José Luis Calleja³⁰, Rosanna Villani³¹, Gaetano Serviddio³¹, Alberto Zanetto³², Sarah Shalaby³², Francesco Paolo Russo³², Rob Bielen^{33,34}, Franco Trevisani³⁵, Calogero Cammà², Jordi Bruix¹, Giuseppe Cabibbo^{2#}, Maria Reig^{1#}.

COLLABORATORS

Alejandro Forner¹, A. Brega⁸⁷, A. De Santis⁹³, Antonio Facciorusso³¹, A. Mario⁹⁴, A. Pellicelli⁹⁰, A. Picardi⁸⁸, Alberto Masotto¹⁷⁰, Annamaria Piscazzi³¹, Antonio Gasbarrini⁸⁴, Adel El Tahan⁷⁰, Agustin Albillos¹²², Ahmad T. Sweedy⁷⁰, Ahmed A. Cordie¹⁶, Ahmed H. Abdelmaksoud¹⁶, Alba Díaz⁶⁰, Alberto Ferrarese³¹, Alessandra Biasiolo²⁷, Alessandra Scuteri⁶³, Alessandro Vitale¹⁴², Alessio Aghemo⁶⁶, Andrea Ribeiro¹, Andrea Mega¹⁶⁶, Anna Darnell⁶¹, Anna Funk⁶⁸, Anna Licata², Antonietta Romano²⁷, Antonio Ciaccio^{73,74}, Antonio Craxi², Antonio Rivero-Juárez¹⁰⁵, Arnaud Fontanet^{68,14}, Ayako Sato¹⁸, Begoña Sacristán¹²⁵, Belén Ruiz-Antorán¹²¹, Boris Revollo⁹⁹, Bruno Sangro⁵⁹, C. Dell'unto⁸⁸, C. Taibi⁸⁹, Camillo Aliberti¹¹⁹, Carmen Alvarez Navascues¹⁴⁰, Céline Dorival²⁸, Chantal

de Galocsy¹⁵³, Chiara Mazzarelli¹⁷, Christian Brixco¹⁵⁰, Christie Perello³⁰, Christophe Moreno¹⁴⁵,
 Christophe Van Steenkiste^{146,156}, Chung-Feng Huang^{11,12}, Claudia Mescoli¹⁴³, Conrado Fernández
 Rodríguez¹³⁵, Cristina Crespi⁶³, Dalia A. Omran¹⁶, Daniel M. Forton¹⁴⁴, David Semela⁹⁷, Diego
 Rincón¹¹⁸, E. Teti⁸⁷, Edoardo G. Giannini⁵⁰, Eleonora Alimenti⁸, Elia Biganzoli⁴⁸, Eman M. Hassan¹⁶,
 Enas Maged⁸¹, Enrica Franceschet³², Erica Villa⁵⁸, Esperanza Merino¹⁰⁰, Eugenio Caturelli¹⁶³, F.
 Ponziani⁸⁶, Fabio Cartabellotta⁴⁷, Fabio Farinati¹⁴³, Fabio Marra¹⁶⁵, Fabio Piscaglia¹⁵⁹, Fabio Tinè⁴¹,
 Fabrice Carrat²⁸, Federica Buonfiglioli¹⁰, Federica Cerini⁵⁵, Filip Janssens^{152,154}, Filippo Olivieri⁵¹,
 Filomena Morisco¹⁶⁷, Francesco Bellanti³¹, Francesco Benanti⁴⁴, Francesco Giuseppe Foschi⁶⁵,
 Francesco Azzaroli¹⁷², Francisco Gea¹²³, Francisco J. Vera-Méndez¹¹⁰, Francisco Jorquera¹³⁷,
 Francisco Rodríguez-Arrondo⁹⁸, Francisco Téllez¹⁰⁶, Francois D'Heygere^{152,157}, Frederik Nevens¹⁵²,
 Fukiko Kawai-Kitahata¹⁸, G. D'offizi⁸⁹, G. Galati⁸⁸, Gabriella Verucchi¹⁰, Gabriele Missale¹⁶⁹,
 Gaetano Bertino⁴², Gaetano Scifo³⁹, Gaia Pellegatta⁵⁰, Gamal Esmat¹⁶, Gasser El-Azab²², Geert
 Robaeys^{33,34,152}, Gerardo Nardone¹⁷¹, Giacomo Germani³², Gian Ludovico Rapaccini¹⁶⁰, Gianluca
 Svegliati-Baroni¹⁶⁸, Gianluigi Vendemiale³¹, Gianpolo Vidili¹⁷³, Giovanna Lunghi⁶⁷, Giovanni
 Mazzola², Giovanni Raimondo⁵³, Giovanni Squadrito⁵³, Giuseppe Mazzella⁶⁴, Guglielmo Borgia⁴⁹,
 Guillermo Ojeda-Burgos¹¹¹, Hans Van Vlierberghe¹⁴⁶, Hayato Nakagawa⁷, Helene Fontaine²⁸, Hideki
 Sakai⁷⁸, Ignazio Scalisi⁴⁵, Ilaria Serio⁵⁶, Inmaculada Fernandez¹²², Irene Cacciola⁴³, Isabelle Vögeli²⁴,
 Javier Ampuero¹³⁶, Javier García-Samaniego¹²⁴, Jean-Pierre Mulkay¹⁴⁸, Jochen Decaestecker^{151,152},
 Johannes Vermehren⁹⁵, Jordi Llaneras¹³², Joseba Portu¹¹⁷, Juan A. Pineda²⁶, Juan Arenas¹³⁹, Juan
 Macías²⁶, Juan Manuel Pascasio¹²⁸, Juan Turnes¹²⁹, Junko Tanaka¹⁷⁷, Kazuyuki Mizuno⁹, Katrien
 Wuyckens^{33,34}, Kazuhiko Koike³⁶, Kenichiro Enooku⁷, Koldo Aguirrebengoa¹¹⁶, Licia La Rocca⁴⁶,
 Lode Van Overbeke¹⁵⁵, Luca Saverio Belli^{17,74}, Luca Valenti⁵², Lucia Cesarini¹⁷, Luigi Bolondi⁶⁴, Luis
 Metola¹¹³, Lydia Giannitrapani², M. Andreoni⁹⁰, Matteo Landriscina³¹, M. Lupo⁸², M. Montalbano⁸⁹,
 M. Pompili⁹¹, M. Siciliano⁸⁴, Makoto Tomita⁷⁹, Mamoru Watanabe¹⁸, Marcial Delgado-Fernández¹⁰⁷,
 Marco Barbàra², Marco Distefano³⁹, Marco Lenzi¹⁰, Marco Senzolo³², Marco Zoli¹⁶³, María A.

García¹¹⁸, Maria Di Marco¹⁶¹, María García-Eliz¹²⁶, María J. Galindo¹⁰², María J. Ríos-Villegas¹⁰⁸,
 María Remedios Aleman-Valls¹¹⁵, Maria Rita Cannavò³⁷, María Varela⁶², Mario Strazzabosco^{73,74},
 Marion Willaime²⁸, Marta Borghi⁸, Marta Montero¹⁰⁴, Martina Gambato⁵⁴, Masato Miyoshi¹⁸, Masaya
 Sato⁷, Massimo Colombo⁶⁶, Massimo Iavarone⁸, Massimo Rugge¹⁴³, Matteo Brunacci⁵⁰, Maurizia
 Rossana Brunetto⁵¹, Maurizio Russello³⁷, Medhat Assem²², Mercedes Ñarairae⁵⁹, Miguel A.
 López-Ruz¹¹², Miguel A. Serra¹³³, Miguel A. Simon¹³⁸, Miguel García-Deltoro¹⁰⁴, Miguel Raffo¹¹⁸,
 Mike Cool^{152,158}, Miyako Murakawa^{18,76}, Mobolaji Odewole²¹, Mohamed M. Nabil¹⁶, Mohamed
 Omar¹¹⁴, Mohammed Eltabbakh⁶⁹, Mohammed Salaheldin Abdelhamid⁶⁹, Moises Diago¹³⁴, Naglaa
 FA Youssef⁷², Naoto Fujiwara⁷, Natalia M. Terreni⁵⁷, Nicola Alessi², Nicole Rich²¹, Oliver
 Waidmann⁹⁵, Paolo Angeli²⁷, Paolo Caraceni⁶⁴, Patrizia Burra³², Patrizia Pontisso²⁷, Pietro
 Andreone¹⁰, Pietro Lampertico⁸, R. Lionetti⁸², Rafael Bañares¹⁴¹, Ramón Vilana⁶¹, Rania Leithy¹⁶,
 Raquel Muñoz¹²², Riccardo Gattai⁵¹, Roberta D'Ambrosio⁸, Roberta Soffredini⁸, Roberto Filomia⁵³,
 Rodolfo Sacco¹⁶⁴, Rosa Maria Morillas¹³¹, Rosanna Tamborra³¹, Ryo Nakagomi⁷, S. Francioso⁸⁷,
 Sabela Lens⁶, Salvatore Madonia³⁸, Salvatore Petta², Satoshi Otani¹⁸, Sayuri Nitta¹⁸, Sei Kakinuma¹⁸,
 Seishin Azuma¹⁸, Sergio Maimone⁵³, Shima Afify⁷¹, Shuichiro Shiina³⁶, Shun Kaneko¹⁸, Silvia
 Fargion⁵², Sofía Ibarra¹⁰¹, Stefan Bourgeois¹⁴⁷, Stefan Zeuzem⁹⁵, Stefano Okolicsanyi^{73,74}, Susana
 Llerena¹²⁷, Tomoyuki Akita¹⁷⁷, Takashi Kumada⁹, Toshifumi Tada⁹, Tamer M. Elbaz¹⁶, Thomas
 Berg⁹⁶, Thomas Vanwolleghem¹⁴⁹, Tomoyuki Tsunoda¹⁸, Toshihiko Nouchi⁷⁷, Tullio Prestileo⁴⁰, U.V.
 Comandini⁸⁹, U.V. Gentilucci⁸⁸, Umberto Cillo¹⁴², V. Giannelli⁸⁵, Valerio Pontecorvi^{73,74}, Ventzislava
 Petrov Sanchez²⁸, Victor de Ledinghen²⁸, Vincenza Calvaruso², Vito Di Marco², Wim Verlinden¹⁴⁹,
 Xavier Torras¹³², Yasmin Omar⁸⁸, Yasuhiro Sone¹⁷⁴, Yasuhiro Itsui^{18,176}, Yoshinari Asaoka⁷, Yu
 Asano¹⁸, Yuji Kondo⁷, Yuji Kaneoka¹⁷⁵, Yusuke Shimakawa⁶⁸.

AFFILIATIONS

1. Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic de Barcelona, IDIBAPS, Universidad de Barcelona, CIBERehd, Barcelona, Spain.
2. Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy.
3. Medical Statistics Core Facility, IDIBAPS, Hospital Clinic Barcelona & Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
4. Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.), University of Palermo, Italy.
5. AP-HP, Hôpital Jean Verdier, Service d'Hépatologie, Bondy; Université Paris 13, Sorbonne Paris Cité, "Equipe labellisée Ligue Contre le Cancer", F-93206 Saint-Denis; Inserm, UMR-1162, "Génomique fonctionnelle des tumeurs solides", F-75000, Paris, France.
6. Liver Unit, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERehd, Barcelona, Spain.
7. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
8. Foundation IRCCS Ca' Granada Ospedale Maggiore Policlinico – Division of Gastroenterology and Hepatology – CRC "A.M. and A. Migliavacca" Center for Liver Disease, Milan, Italy.
9. Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki Japan.
10. Research Centre for the Study of Hepatitis, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Italy.
11. Hepatobiliary Division, Department of Internal Medicine, and Hepatitis Center Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
12. Faculty of Internal Medicine and Hepatitis Research Center, School of Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
13. Laboratoire MESuRS (EA 4628), Conservatoire National Des Arts et Métiers, Paris, France.
14. Unité PACRI, Institut Pasteur, Conservatoire National des Arts et Métiers, Paris, France.
15. Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
16. Endemic Medicine and Hepato-Gastroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
17. Department of Hepatology and Gastroenterology, Liver Unit, Niguarda Hospital, Milan, Italy.
18. Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
19. Institute of Education, Tokyo Medical and Dental University, Tokyo, Japan.
20. Department of Liver Disease Control, Tokyo Medical and Dental University, Tokyo, Japan.
21. Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, United States.
22. Hepatology, National Liver Institute, Shebeen El-Kom, Egypt.
23. Policlinico Tor Vergata, Liver and Transplant Unit, Rome, Italy.
24. University Clinic for visceral Surgery and Medicine Inselspital Bern. Bern, Switzerland.
25. Hepatology, Department of Biomedical Research, University of Bern. Bern, Switzerland.
26. Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla.
27. Department of Medicine-DIMED, Padua University, University Hospital, Clinica Medica 5, Referring Center for Liver Diseases.
28. l'Agence de recherche ANRS (France REcherche Nord&Sud Sida-HIV Hépatites), Paris, France.

29. Hospital Universitario Marques de Valdecilla, IDIVAL, Santander and Facultad de Medicina, Universidad de Cantabria, Spain.
30. Liver Unit, Hospital Universitario Puerta de Hierro, CIBERehd, IDIPHIM, Madrid, Spain.
31. Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
32. Gastroenterology/Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology Unit, Padua University Hospital, Padua, Italy.
33. Faculty of Medicine and Life sciences, Hasselt University, Hasselt, Belgium.
34. Department of Gastro-Enterology and Hepatology, Ziekenhuis-Oost Limburg, Genk, Belgium.
35. Department of Medical and Surgical Sciences, Semeiotics Unit, Alma Mater Studiorum – University of Bologna, Bologna, Italy.
36. Department of Gastroenterology, Juntendo University, Japan.
37. Epatologia, A.O. Cannizzaro, Catania, Catania, Italy.
38. Medicina Interna, A.O. Villa Sofia-Cervello, Palermo, Italy.
39. Malattie Infettive, Ospedale di Siracusa, Siracusa, Italy.
40. Malattie Infettive, ARNAS Civico-Di Cristina-Benefratelli, Palermo, Italy.
41. Gastroenterologia, A.O. Villa Sofia-Cervello, Palermo, Italy.
42. Medicina Interna e d'Urgenza, A.O.U.P Vittorio Emanuele, Catania, Italy.
43. Department of Internal Medicine, University of Messina, Messina, Italy.
44. Malattie Infettive, A.O. Cannizzaro, Catania, Italy.
45. Medicina Interna, Ospedale di Castelvetrano, Castelvetrano, Italy.
46. Malattie Infettive, ARNAS Garibaldi-Nesima, Catania, Italy.
47. Medicina Interna, Ospedale Buccheri La Ferla, Palermo, Italy.
48. Unit of Medical Statistics, biometry and bioinformatics, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Milan, Italy.
49. Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Napoli 'Federico II', Napoli, Italy.
50. Department of Internal Medicine, Gastroenterology Unit, University of Genova, IRCCS Policlinico San Martino, Genova, Italy.
51. Department of Clinical and Experimental Medicine, Hepatology and Liver Physiopathology Laboratory and Internal Medicine, University of Pisa, Pisa, Italy.
52. Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milano, Italy.
53. Department of Clinical and Experimental Medicine, Clinical and Molecular Hepatology Unit, University of Messina, Messina, Italy.
54. Multivisceral Transplant Unit, Department of Surgery, Oncology, and Gastroenterology, Padova University Hospital, Padova, Italy.
55. Division of Hepatology, Ospedale San Giuseppe, Università degli Studi di Milano, Milano, Italy.
56. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
57. Division of Gastroenterology, Valduce Hospital, Como, Italy.
58. Gastroenterology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
59. Unidad de Hepatología, Clínica Universidad de Navarra, IDISNA, CIBERehd, Pamplona, Spain.
60. Department of Pathology, BCLC Group, Hospital Clínic Barcelona, IDIBAPS, University of Barcelona, Spain.
61. Department of Radiology, BCLC Group, Hospital Clínic Barcelona, University of Barcelona, Spain.
62. IUOPA.ISPA, Liver Unit, Hospital Universitario Central de Asturias, Oviedo, Spain.

63. Department of Digestive Diseases, Policlinico S.Orsola-Malpighi, Bologna, Italy.
64. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Italy.
65. Department of Internal Medicine, Ospedale per gli Infermi of Faenza, Faenza, Italy.
66. Department of Internal Medicine, Humanitas Clinical and Research Center IRCCS, Rozzano-Milan, Italy.
67. Microbiology and Virology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
68. Emerging Disease Epidemiology Unit, Institut Pasteur, Paris, France.
69. Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
70. New Cairo Viral Hepatitis Treatment Unit, Cairo, Egypt.
71. National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
72. Medical Surgical Nursing Department, Faculty of Nursing, Cairo University, Cairo, Egypt.
73. Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
74. International Center for Digestive Health, University of Milan-Bicocca, Milan, Italy.
75. Department of Diagnostic and Interventional Radiology, Faculty of Medicine, Cairo University, Cairo, Egypt.
76. Department of Clinical Laboratory, Tokyo Medical and Dental University, Japan.
77. Showa General Hospital, Tokyo, Japan.
78. Kashiwa Municipal Hospital, Chiba, Japan.
79. Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan.
80. Oncology, National Liver Institute, Shebeen El-Kom, Egypt.
81. Epidemiology, National Liver Institute, Shebeen El-Kom, Egypt.
82. National Institute for Infectious Disease Spallanzani, Infectious Diseases- Hepatology.
83. Sapienza University of Rome, Department of Clinical Medicine.
84. Internal Medicine and Gastroenterology Unit, Policlinico Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy.
85. San Camillo Forlanini Hospital, Liver Transplantation.
86. A. Gemelli Hospital, Gastroenterology and Hepatology.
87. Tor Vergata University Hospital, Department of Infectious Disease.
88. University Campus Biomedico, Internal Medicine and Hepatology Unit.
89. National Institute for Infectious Diseases Spallanzani, Infectious Diseases-Hepatology.
90. Policlinico Tor Vergata, Department of Infectious Disease.
91. A. Gemelli Hospital, Internal Medicine, Gastroenterology and Hepatology.
92. San Camillo Forlanini Hospital, Department of Liver Transplantation.
93. Sapienza University of Rome, Gastroenterology Unit.
94. Tor Vergata University Hospital, Liver and Transplant Unit .
95. Department of Medicine I, Division of Gastroenterology and Hepatology, University Hospital Frankfurt, Frankfurt am Main, Germany.
96. Department of Internal Medicine, Neurology and Dermatology, Medical Clinic of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.
97. Division of Gastroenterology and Hepatology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
98. Hospital Universitario de Donostia, San Sebastián.
99. Hospital German Trias i Pujol, Badalona.
100. Hospital General Universitario de Alicante, Alicante.
101. Hospital de Basurto, Bilbao.
102. Hospital Clínico Universitario de Valencia.
103. Hospital Universitario y Politécnico La Fe.
104. Hospital General de Valencia, Valencia.

105. Instituto Maiomónides de Investigación Biomédica de Córdoba (IMIBIC). Hospital Universitario Reina Sofía, Córdoba.
106. Hospital Universitario de Puerto Real. Hospital de La Línea. Instituto de Investigación e Innovación en Ciencias Biomédicas de la provincia de Cádiz (INiBICA), Cádiz.
107. Hospital Regional Universitario de Málaga, Málaga.
108. Hospital Universitario Virgen Macarena, Sevilla.
109. Hospital de Galdakao, Galdakao.
110. Hospital General Universitario de Santa Lucía, Cartagena.
111. Hospital Virgen de la Victoria, Málaga.
112. Hospital Universitario Virgen de las Nieves, Granada.
113. Hospital de San Pedro, Logroño.
114. Complejo Hospitalario de Jaén, Jaén.
115. Hospital Universitario de Canarias, San Cristóbal de La Laguna, Tenerife.
116. Hospital de Cruces, Bilbao.
117. Hospital Txagorritxu, Vitoria.
118. Complejo Hospitalario de Huelva, Huelva, Spain.
119. Department of Interventistic Radiology, Oncologic Institute of Veneto Region, IOV.
120. Hospital General Universitario Gregorio Marañón, Facultad de Medicina de la Universidad Complutense and CIBERehd, Madrid, Spain.
121. Hospital Universitario Puerta de Hierro, Madrid, Spain.
122. Hospital Universitario 12 de octubre, Madrid, Spain.
123. Hospital Universitario Ramon y Cajal, Madrid, Spain.
124. Hospital Universitario La Paz, CIBERehd, IdiPAZ, Madrid, Spain.
125. Hospital San Pedro, Logroño, Spain.
126. Hospital Universitario La Fe and CIBERehd, Valencia, Spain.
127. Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain.
128. Hospital Universitario Virgen del Rocío and CIBERehd, Seville, Spain.
129. Complejo Hospitalario Universitario de Pontevedra and IISGS, Spain.
130. Hospital Santa Creu i Sant Pau and CIBERehd, Barcelona, Spain.
131. Hospital Germans Trias I Pujol and CIBERehd, Badalona, Spain.
132. Hospital Universitario Vall D'Hebrón, Barcelona, Spain.
133. Hospital Clínico de Valencia, Valencia, Spain.
134. Hospital Universitario General de Valencia, Valencia, Spain.
135. Hospital Universitario Fundación Alcorcón, Madrid, Spain.
136. Hospital Universitario Virgen del Rocío, IBIS and CIBERehd, Spain.
137. Complejo Asistencial Universitario León, León, IBIOMED and CIBERehd, Spain.
138. Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
139. Hospital Universitario Donostia, San Sebastian, Spain.
140. Hospital Universitario Central de Asturias, Oviedo, Spain.
141. Hospital General Universitario Gregorio Marañón, Facultad de Medicina de la Universidad Complutense and CIBERehd, Madrid, Spain.
142. Hepatobiliary Surgery and Liver Transplantation Unit, Department of Surgery, Oncology and Gastroenterology Unit.
143. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
144. Department of Gastroenterology and Hepatology, St. George's University Hospitals National Health Service Foundation Trust, London, United Kingdom.
145. Department of Gastro-Enterology and Hepatopancreatology, Erasme Hospital, Brussels, Belgium.

146. Department of Hepatology and Gastro-Enterology, University Hospitals Gent, Gent, Belgium.
147. Department of Gastro-Enterology and Hepatology, ZNA Stuivenberg, Antwerp, Belgium.
148. Department of Gastro-Enterology and Hepatology, Hôpital Saint-Pierre, Brussels, Belgium.
149. Department of Gastro-Enterology and Hepatology, Antwerp University Hospital, Edegem, Belgium.
150. Department of Gastroenterology and Digestive Oncology, CHR Citadelle, Liège, Belgium.
151. Department of Gastro-Enterology and Hepatology, AZ Delta, Roeselare, Belgium.
152. Department of Gastro-Enterology and Hepatology, University Hospitals KULeuven, Leuven, Belgium.
153. Department of Gastro-Enterology and Hepatology, Hôpital HIS Bracops, Anderlecht, Brussels, Belgium.
154. Department of Gastro-Enterology and Hepatology, Jessa Hospital, Hasselt, Belgium.
155. Department of Gastro-Enterology and Hepatology, AZ Sint Maarten, Mechelen, Belgium.
156. Department of Gastro-Enterology and Hepatology, AZ Maria Middelaers, Gent, Belgium.
157. Department of Gastro-Enterology and Hepatology, AZ Groeninge, Kortrijk, Belgium.
158. Department of Gastro-Enterology and Hepatology, AZ Damiaan, Oostende, Belgium.
159. Azienda Ospedaliero-Universitaria S. Orsola-Malpighi, Internal Medicine–Piscaglia Unit, Bologna, Italy.
160. Gastroenterology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy.
161. Medicine Unit, Bolognini Hospital, Seriate, Italy.
162. Gastroenterology Unit, Belcolle Hospital, Viterbo, Italy.
163. Department of Medical and Surgical Sciences, Internal Medicine–Zoli Unit, Alma Mater Studiorum – University of Bologna, Bologna, Italy.
164. Gastroenterology and Digestive Endoscopy Unit, Foggia University Hospital, Foggia, Italy.
165. Department of Experimental and Clinical Medicine, Internal Medicine and Hepatology Unit, University of Firenze, Firenze, Italy.
166. Gastroenterology Unit, Bolzano Regional Hospital, Bolzano, Italy.
167. Department of Clinical Medicine and Surgery, Gastroenterology Unit, University of Napoli "Federico II", Napoli, Italy.
168. Gastroenterology Unit, Polytechnic University of Marche, Ancona, Italy.
169. Infectious Diseases and Hepatology Unit, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.
170. Gastroenterology Unit, Ospedale Sacro Cuore Don Calabria, Negrar, Italy.
171. Department of Clinical Medicine and Surgery, Hepato -Gastroenterology Unit, University of Napoli "Federico II", Napoli, Italy.
172. Department of Surgical and Medical Sciences, Gastroenterology Unit, Alma Mater Studiorum – University of Bologna, Bologna, Italy.
173. Department of Medical, Surgical and Experimental Sciences. Clinica Medica Unit, University of Sassari, Azienda Ospedaliero-Universitaria of Sassari, Sassari, Italy.
174. Department of Radiology, Ogaki Municipal Hospital, Ogaki, Japan.
175. Department of Surgery, Ogaki Municipal Hospital, Ogaki, Japan.
176. Department of General Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
177. Department of Epidemiology, Infectious Disease Control, and Prevention, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.

SHORT TITLE: Hepatocellular Carcinoma Recurrence After Direct-acting Antivirals

Word count: 3272

Abstract: 248

Tables: 3

Figures: 3

KEYWORDS

Hepatocellular carcinoma, DAA, recurrence, survival, metanalysis, propensity score matching

* The 2 authors contributed equally.

**The 2 authors contributed equally.

Corresponding Authors:

- Giuseppe Cabibbo: Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy.
- Maria Reig: BCLC group, Liver Unit, IMDiM, CIBERehd, IDIBAPS, Hospital Clínic, c/ Villarroel, 170, Escala 11, 4a planta, 08036 Barcelona. Spain. Tel.: +34 932279803, fax: +34 932275792. E-mail address: mreig1@clinic.cat

ABSTRACT

Objective

The benefit of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) following successful treatment of early hepatocellular carcinoma (HCC) is a highly controversial topic despite the data reported from North America. This meta-analysis of individual patient data assesses the risk of HCC recurrence after DAAs.

Design

We pooled 977 consecutive patients from 21 published studies of HCV-related cirrhosis and HCC, who had achieved complete radiologic response after surgical or locoregional treatments and were subsequently treated with DAAs (DAA group). Risk of recurrence or death was expressed as HCC recurrence per 100 person-year (100PY) or death per 100PY. Propensity score matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified by random effect Poisson.

Results

Recurrence rate and death risk per 100PY in DAA-treated patients was 20 (95%CI:13.9-29.8, $I^2=74.6\%$) and 5.7 (95%CI:2.5-15.3, $I^2=54.3$), respectively. Heterogeneity among studies was high for both outcomes. Predictive factors of recurrence were logarithm of alpha-fetoprotein (RR=1.11[95%CI:1.03-1.19];p-value=0.01, per 1 log of ng/ml), history of HCC recurrence before DAA-initiation (RR=1.11[95%CI:1.07-1.16];p-value<0.001), ECOG-PS (2 vs 0, RR=4.35[95%CI:1.54-11.11] and 2 vs 1, RR=3.7[95%CI:1.3-11.11];p-value=0.01) and tumor burden prior to HCC treatment (multifocal vs. solitary nodule, RR=1.75[95%CI:1.25-2.43];p-value<0.001).

Relative risk between DAA-exposed and unexposed in propensity score matched patients (167 pairs) remains inconclusive, with no statistically significant differences (RR=0.64 [95%CI:0.37-1.1];p-value=0.1).

Conclusion

The effect of the DAA exposure on HCC recurrence risk was inconclusive in this study. Active surveillance is justified in this population for whom no effective adjuvant treatment is available.

INTRODUCTION

The first reports[1,2] about the potential increased risk of hepatocellular carcinoma (HCC) recurrence in patients with successfully treated HCC who subsequently received direct-acting antiviral (DAA) treatment triggered major interest in the topic. Almost all centres in the world published their experience or presented it at liver-oncology meetings. Furthermore, systematic reviews and cumulative meta-analyses addressed the issue[3–7], but while such approach yielded a suggestion for a reduced recurrence risk, the heterogeneity across studies prevented a robust message that would end the controversy. Indeed, despite applying statistical tools to decrease the rate of heterogeneity, this remained unacceptably high, ranging from 80.5%[3] to 96.7%[7]. Thus, the optimism about a reduction of recurrence risk by HCV therapy was not sustained by scientific evidence. In that sense, cohort studies included in the meta-analytic assessment suffer from patient heterogeneity at baseline, different follow-up time and different follow-up procedures to detect recurrence. The multicentre retrospective cohort studies by Singal et al[8,9] ~~done only in North America~~ suggested no increased recurrence and improved survival after DAA treatment ~~and improved survival~~ but only included patients from the U.S. and ~~then highlighting~~ there remain a need for systematic review of international data given differences in patients characteristics and HCC practice patterns.

Since the controversy is still open, all guidelines about HCC[10] and antiviral therapy[11–14] describe the limitations of the current data. The unequivocal answer would be obtained through a randomized controlled trial (RCT) with allocation to treatment or no treatment and a homogeneous follow-up strategy. Such RCTs that would directly compare DAAs versus no-DAAs are considered not feasible, non-ethical or not-timely, or all at the same time. In that sense, long term survival of these patients is dictated by the HCC-recurrence or progression of the tumour, and by the development of complications due to progression of liver disease. The latter represents the one of

the drivers of death in HCV-viremic patients with successfully treated early HCC[2], and it has been showed that DAAs could improve overall survival through a reduction of the risk of hepatic decompensation[8,15]. Therefore, the acceptance of a RCT to assess the risk of HCC recurrence is precluded[15].

Because of this situation of uncertainty and unfeasibility to expect results from an RCT, we designed an international, multicentre study using individual data. This would overcome the limitations associated with the use of aggregate data as in prior meta-analyses, increasing the relevance of the statistical analysis and improving the estimates of effect size. The present meta-analysis using individual patient data (MIPD) aimed to: (1) assess the recurrence rate of HCC in DAA-treated patients after complete response; (2) identify risk factors for HCC recurrence after DAA treatment. Finally, we incorporated a propensity score analysis to assess the impact of DAA therapy as compared vs a DAA-unexposed control group derived from the Italian curated prospective database ITA.LI.CA.

MATERIALS AND METHODS

Meta-analysis using individual patient data (MIPD) of DAA-exposed patients.

The current MIPD was designed to pool the data of individuals from different studies evaluating the risk of HCC recurrence after DAA exposure in HCV-infected cirrhotic patients with previous successful treatment for HCC [16].

This study complied with the principles of the Declaration of Helsinki and its appendices, and local and national laws. It was approved by the Research Ethics Committee of the Hospital Clínic of Barcelona (HCB/2019/0030) and registered in PROSPERO database (CRD42020133457-https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=133457).

Studies were included in the qualitative analysis if they met all of the following criteria: a) data in English language with full-text accessibility/presentation or poster/oral presentation; b) target

population of the original paper was HCC patients who received DAAs after HCC treatment; c) the study had to assess the risk of developing HCC recurrence after DAA treatment; d) report HCC recurrence of patients; e) report the date of prior HCC treatment. A systematic search for records up to April 3, 2018 in PubMed Central/MEDLINE was performed with different combinations of keywords. The search details are reported in Supplementary Material.

A Data Transfer Protocol (DTP) was written according to the European regulation (General Data Protection Regulation (GDPR) 2016/679 of the European Parliament and of the Council of April 27, 2016 and approved by each cohort responsible. Centres were requested to provide baseline data and follow-up events and dates. The complete list of variables extracted from the included studies and the DTP document are reported in Supplementary Material.

The primary outcomes were - HCC recurrence rate, defined as the number of patients per 100 patient-year (100PY) who previously obtained HCC complete response (CR) and that developed HCC after DAA treatment, and - death rate per 100PY.

DAA-unexposed patients' cohort

Data from the 328 DAA-unexposed patients who acted as controls were obtained from the retrospective study of prospective ITA.LI.CA. database[17] enrolled from 2007 to 2015. They were HCV-related compensated cirrhotic patients with a first diagnosis of early HCC (BCLC 0/A), who had achieved CR after ablation or resection and who had not been treated with DAAs.

Statistical analysis

Quantitative variables were expressed as median and interquartile range [IQR:25th-75th percentiles]. Categorical variables were described as absolute frequencies and percentages (%).

For MIPD analysis of the DAA-exposed patients' cohort, pooled recurrences of HCC or death were expressed as number of events per 100PY. Rates and 95% confidence intervals (95%CI) were estimated by means of Poisson models using a random effects *one-stage* step approach and including as offset the logarithm of the radiological follow-up time. Heterogeneity was evaluated by means of the I^2 and the Q heterogeneity test. Values of I^2 around 25%, 50% and 75% were considered, respectively as: low, moderate and high levels of heterogeneity[18]. Q heterogeneity test was considered significant when p-values were <0.1 . Sensitive analyses were conducted to explore the potential sources of heterogeneity and included assessment by subgroups, univariate or multivariate Poisson regression models and leave-one-out strategy, using the same *one-stage* random effects approach. Prognostic factors for recurrence were analysed using univariate and multivariate Poisson regression models, including in the multivariate analysis those variables with $p\text{-value}<0.1$ on the univariate testing.

Propensity score (PS) matching (PSM) was performed between the DAA-exposed and unexposed patients. Matching 1:1 was conducted using the greedy nearest neighbour approach with a caliper of 0.06 for the predicted probability. The balance between cohorts, before and after PSM was assessed by standardized mean differences (STD). $\text{STD}>10\%$ were considered unbalanced[19–21]. Details of PS model are described in supplementary materials.

The comparison of risk of recurrence between matched patients was performed by relative risks and their 95%CI, estimated using the same Poisson model but including also the DAA-unexposed group. A sensitivity survival analysis was conducted for overall survival using restricted mean survival time (RMST) methods since the proportional-hazards assumption did not hold[22]. The restricted time (τ) was established at the time of the last observed death.

The level of significance was set at the two-sided 5% level. All analyses were performed with SAS 9.4 software (SAS Institute, Cary, NC, USA).

RESULTS

Baseline characteristics

Initial search found 87 studies. After first assessment, 32 studies meeting the inclusion criteria were invited to participate. After first contact, 23 corresponding authors of each study sent the data, of which 21 were finally included[1,2,9,23–40]. Two full studies involving 67 patients were excluded because they did not fulfil the prespecified data requirements. Thus, there were 977 DAA-treated patients: 12 retrospective and 9 prospective, including 12 full-length paper, 5 abstracts and 4 Letters to the Editor (Figure 1). The studies baseline characteristics are reported in Table 1, and the individual characteristics of the included patients are reported in Supplementary Table S1. Most of the DAA treated patients were male (63%), with a median age of 67.9 years, and Child-Pugh class A (88%). More than half (52.8 %) met Milan criteria, 38.6% had solitary HCC at tumour diagnosis, 7.1% had multifocal HCC and less than 0.5% of the cohort had extrahepatic spread or vascular invasion. Performance status (ECOG-PS) was 0 in 93.3% of the patients and the most frequent treatment was ablation (47.3%), followed by resection (31%) and chemoembolization (15.3%). Sustained virological response (SVR) rate in the studies ranged from 60% to 98.2%.

Table 1. Characteristics of included patients

	Males (%)	Child-Pugh (A/B/C,%)	ECOG-PS (0/1,%)	Extrahepatic Spread / Vascular Invasion (Yes,%)	Esophageal Varices / Ascites / AHT / HBV / DM / Alcohol consumption (Yes,%)	Images used for CR assessment (MR/CT/Others,%)	Radiological follow-up (Yes,%)	Waiting list for LT (Yes,%)	SVR (Yes,%)
Conti F. et al., 2016 ³⁷	67.2	83 / 17 / 0	100 / 0	0 / 0	41.4 / 25.9 / 0 / 3.5 / 34.5 / 6.9	7 / 29 / 64	100	5.2	89.7
Minami T. et al., 2016 (L) ³⁶	59	98 / 2 / 0	100 / 0	0 / 0	10.3 / 0 / 15.1 / 0 / 21.9 / 50.7	25 / 75 / 0	100	0	91.8
ANRS, 2016 ³⁴	80	83 / 17 / 0	89 / 11	0 / 0	20 / 20 / 20 / 0 / 10 / 90	60 / 30 / 10	100	10	80
Reig M. et al., 2016 ¹	68.8	86 / 6 / 3	100 / 0	0 / 0	28.6 / 5.2 / 0 / 1.3 / 0 / 0	47 / 17 / 36	100	0	67.5
HEPADAT, 2017 (†) ³⁸	72.4	92 / 7 / 1	84 / 13	0 / 0	18.4 / 10.3 / 48.3 / 4.6 /	19 / 32 / 49	100	0	92

					24.1 / 31				
Zavaglia C. et al., 2017 (L) ³³	44.7	74 / 26 / 0	92 / 8	0 / 2.6	31.6 / 18.4 / 15.8 / 0 / 21.1 / 7.9	50 / 42 / 8	100	2.6	92.1
Kohla M. et al., 2017 (††) ⁴⁰	76.9	85 / 15 / 0	100 / 0	0 / 0	30.8 / 0 / 38.5 / 0 / 26.9 / 0	0 / 100 / 0	0	0	69.2
Villani R. et al., 2017 (*) ³¹	100	80 / 20 / 0	100 / 0	0 / 0	0 / 0 / 40 / 0 / 60 / 0	40 / 60 / 0	100	0	60
Cavalletto L. et al., 2017 (*) ³⁶	58.3	75 / 25 / 0	25 / 58	0 / 0	83.3 / 33.3 / 25 / 0 / 25 / 41.7	33 / 58 / 8	100	8.3	83.3
Tsai PC. et al., 2017 (L) ³⁰	41.3	70 / 0 / 0	66 / 34	0 / 2.2	4.4 / 0 / 0 / 4.4 / 21.7 / 4.4	9 / 20 / 71	100	13	100
Nagata H. et al., 2017 ²⁷	60	97 / 3 / 0	97 / 3	3.3 / 0	46.7 / 3.3 / 6.7 / 6.7 / 20 / 43.3	53 / 47 / 0	100	0	96.7
Kolly P. et al., 2017 (L) ²³	68.8	81 / 19 / 0	50 / 44	0 / 0	50 / 18.8 / 37.5 / 6.3 / 18.8 / 6.3	31 / 69 / 0	100	56.3	68.8
Calleja JL. et al., 2017 ³⁵	50	63 / 13 / 0	100 / 0	0 / 0	37.5 / 12.5 / 50 / 0 / 25 / 0	75 / 13 / 13	100	25	87.5
El Kassas M. et al., 2017 ³⁹	65.1	98 / 2 / 0	93 / 7	0 / 0	53.5 / 0 / 46.5 / 0 / 32.6 / 0	0 / 100 / 0	0	0	74.4
Cabibbo G. et al., 2017 ²	60.3	87 / 13 / 0	96 / 4	0 / 0	58.9 / 11.4 / 45.4 / 1.4 / 31.9 / 0	23 / 77 / 0	99.3	0	96.5
Masetti C. et al., 2018 (**) ²⁴	62.5	92 / 4 / 4	100 / 0	4.2 / 0	37.5 / 4.2 / 29.2 / 0 / 20.8 / 25	4 / 42 / 54	100	4.2	91.7
Toyoda H. et al., 2018 ²⁹	52.8	96 / 4 / 0	100 / 0	0 / 0	27.1 / 2.9 / 47.1 / 0 / 57.1 / 27.1	100 / 0 / 0	100	0	95.7
Ashraf Omar A. et al., 2018 ³²	89.5	87 / 13 / 0	79 / 21	0 / 0	0 / 0 / 2.6 / 0 / 23.7 / 0	74 / 26 / 0	100	2.6	94.7
Merchant N. et al., 2018 ²⁵	87.5	88 / 6 / 6	75 / 25	0 / 0	0 / 0 / 0 / 0 / 0 / 0	38 / 31 / 31	0	0	93.8
Singal A. et al., 2019 ⁹	73.3	87 / 13 / 0	97 / 3	0 / 0	0 / 6.7 / 0 / 0 / 0 / 0	53 / 47 / 0	0	0	86.7
Degasperi E. et al., 2019 ³⁸	58.9	89 / 11 / 0	100 / 0	0 / 0	46.4 / 14.3 / 41.1 / 3.6 / 14.3 / 21.4	18 / 68 / 14	94.6	0	98.2

*: Works presented on EASL2017; **: Works presented on EASL2018; †: Works presented on AASLD2017; ††: Works presented on ILCA2017; L: Letter to the Editor; AHT: Arterial Hypertension; HBV: Hepatitis B Virus; DM: Diabetes Mellitus; CR: Complete Response; MR: Magnetic Resonance; CT: Computed Tomography; LT: Liver Transplant; SVR: Sustained Virological Response; ECOG-PS: Eastern Cooperative Oncology Group Performance Status

Outcomes

The median follow-up of the whole cohort was 15 [IQR:9–22.6] months. During this period, 41.8% patients developed HCC recurrence and 12.9% have died. The characteristics of patients at HCC recurrence are reported in Supplementary Table S2.

The rate of decompensation was not analysed because up to 296 patients (>30%) did not have this data available. Indeed, the trigger for decompensation and its date were not reported in 31.9% of the patients.

HCC recurrence

The pooled HCC recurrence rate per 100PY was 20 (95%CI: 13.9-29.8). Heterogeneity among studies was very high for the main analysis ($I^2 = 74.6\%$, 95%CI: 61.6%-83.3%; p-value<0.001) (Figure 2). Predictive factors of recurrence at multivariate analysis were logarithm of AFP (RR= 1.11 [95%CI: 1.03–1.19], per 1 log of ng/mg increase; p-value=0.01), number of previous HCC recurrence before DAA initiation (RR= 1.11 [95%CI: 1.07–1.16]; p-value<0.001), ECOG-PS (2 vs 0, RR = 4.35 [95%CI: 1.54–11.11] and 2 vs 1, RR = 3.7 [95%CI: 1.3–11.11]; p-value=0.01) and tumor burden of last HCC before DAA initiation (<=3 nodules and <=3cm vs. Solitary nodule, RR = 1.47 [95%CI: 1.2–1.85] and multifocal vs. solitary nodule, RR = 1.75 [95%CI: 1.25–2.43]; p-value<0.001)(Table 2).

Table 2. Prognostic baseline factors for HCC recurrence

Parameter	Contrast	Univariate		Multivariate	
		RR (95%CI)	P-value	RR (95%CI)	P-value
Age (Years)		2.56 (2.55-2.56)	<0.001		
Gender	Male vs. Female	1.22 (0.99-1.52)	0.06		
Weight		2.55 (2.55-2.56)	<0.001		
Height		2.69 (2.58-2.81)	0.6		
MELD score		1.79 (1.68-1.93)	<0.001		
Presence of HBV	Yes vs. No	1.12 (0.49-2.56)	0.8		
Presence of HIV	Yes vs. No	0.52 (0.08-3.26)	0.3		
Child-Pugh			<0.001		

	A vs. B	0.77 (0.56-1.05)			
	A vs. C	1.55 (0.21-11.28)			
	A vs. Non-Cirrhotic	2.08 (0.85-5.08)			
	B vs. C	2.02 (0.27-14.99)			
	B vs. Non-Cirrhotic	2.71 (1.06-6.9)			
	C vs. Non-Cirrhotic	1.34 (0.15-11.74)			
Total bilirubin (mg/dl)		2.25 (1.66-3.69)	0.4		
ALT (UI/L)		2.63 (2.63-2.64)	<0.001		
Log(AST, UI/L)		1.44 (1.43-1.46)	<0.001		
Alkaline phosphatase (UI/L)		2.7 (2.69-2.7)	<0.001		
Hemoglobin (g/dl)		2.54 (2.53-2.56)	<0.001		
Creatinine (mg/dl)		2.52 (2.44-2.62)	<0.001		
Prothrombin time (%)		2.56 (2.53-2.58)	<0.001		
Platelets (x10 ⁹)		2.72 (2.72-2.72)	0.1		
Leucocyte (x10 ⁹)		2.71 (2.69-2.74)	0.8		
Neutrophil (x10 ⁹)		2.72 (2.71-2.72)	<0.001		
Number of previous HCC recurrence		1.86 (1.78-1.96)	<0.001	1.11 (1.07-1.16)	<0.001
Ascites	Yes vs. No	0.85 (0.57-1.28)	0.4		
Encephalopathy	Yes vs. No	0.86 (0.25-3.03)	0.8		
Esophageal varices	Yes vs. No	0.97 (0.76-1.23)	0.8		
ECOG-PS	1 vs. 0	1.1 (0.75-1.61)	<0.001	1.14 (0.78-1.64)	0.01
	2 vs. 0	3.7 (1.32-10)		4.35 (1.54-11.11)	
	2 vs. 1	3.33 (1.14-10)		3.7 (1.3-11.11)	
Log(AFP, ng/ml)		1.14 (1.05-1.41)	<0.001	1.11 (1.03-1.19)	0.01
Tumor burden of last treatment before DAA initiation	<=3 nodules and <=3cm vs. Solitary nodule	1.38 (1.12-1.72)	<0.001	1.47 (1.2-1.85)	<0.001
	Multifocal vs. Solitary nodule	1.72 (1.23-2.38)		1.75 (1.25-2.43)	
	Multifocal vs. <=3 nodules and <=3cm	0.81 (0.59-1.11)		0.84 (0.63-1.16)	

HCV: Hepatitis C Virus; HBV: Hepatitis B Virus; HIV: human immunodeficiency virus; HCC: Hepatocellular carcinoma; ALT: Alanine aminotransferase; DAA: Direct Acting Antiviral agents; NE: Not estimable; 95%CI: 95% confidence interval; RR: Relative risk; ECOG-PS: Eastern Cooperative Oncology Group Performance Status

Additional exploratory multivariate regression models in the whole population were done but no model improved the high heterogeneity rate.

Details of multivariate regression models, as well as the leave-one-out analysis, and the stratified analyses are described in Supplementary Table S3.

A regression model was also done in the 377 patients with solitary nodules before starting DAA. The recurrence rate per 100PY in these patients was 16.5 (95%CI: 9.1–33.47). The rate per 100PY in these patients without prior history of recurrence was 13.7 (95%CI:6.2–35.9); Table 3.

Table 3. Regression models on patients with solitary nodules.

	Number of Events	Number of Patients	Recurrence rate per 100PY (95%CI)	I² (95%CI)	heterogeneity test (p-value)
Solitary nodule	134	377	16.54 (9.12-33.47)	38.5 (0.5-62)	0.04
Solitary nodule without history previous recurrence	69	223	13.69 (6.16-35.94)	0 (0-100)	0.6
Solitary nodule without history previous recurrence treated with resection	20	63	13.7 (3.95-55.09)	0 (0-18.2)	>0.9
Solitary nodule history of 1 previous recurrence	36	88	20.92 (7.9-71.42)	0 (0-97)	0.5
Solitary nodule history of 1 previous recurrence treated with resection	7	25	19.9 (5.8-145.88)	0 (0-30.2)	>0.9

95%CI: 95% confidence interval

The subgroup analysis of HCC recurrence per 100PY according to the time between the last CR registration and DAA initiation (≥ 3 months vs > 3 months; ≤ 6 months vs > 6 months and ≤ 12 months vs > 12 months) in the whole cohort and according to the baseline tumour burden is reported in Supplementary Table S4. We did not observe an impact of the time elapsed between CR registration and DAA treatment initiation.

Death

The pooled death rate per 100PY was 5.7 (95%CI: 2.5-15.3). Heterogeneity among studies was high [$I^2 = 54.25\%$, (95%CI: 26.87%-71.38%); p -value <0.01](Figure 3).

Risk factors for HCC recurrence in DAA-exposed and DAA-unexposed patients

Supplementary Table S5 shows the baseline characteristics of 1,305 HCV patients (977 DAA-exposed and 328 DAA-unexposed) who achieved complete radiological response after HCC treatment. The STD were more than 10% (and 20%) in 12 (and 7) out of 18 variables analysed in both cohorts. After matching 1 control (DAA-unexposed patient) for 1 DAA-exposed patient, 167 pairs were obtained (N=334). The control cohort represents the 50.1% of patients of the ITA.LI.CA. cohort[17]. Supplementary Table S6 describes the baseline characteristics of the matched cohort, where the STD was $<10\%$ in all variables.

All matched patients had single HCC or HCC within Milan Criteria (BCLC 0/A) treated by resection or ablation.

The recurrence rate per 100PY (95%CI) was 23.21 (95%CI: 16.23-33.19) in DAA-unexposed patients and 14.75 (95%CI: 9.78-22.24) in DAA-exposed patients [RR=0.64 (95%CI: 0.37 - 1.1); p -value=0.1].

The recurrence rate per 100PY (95%CI) in DAA-exposed patients with single HCC was 14.3 (95%CI: 10.5–19.6) and 15.9 (95%CI: 9.78–25.9) in Milan-in patients.

Overall survival in DAA-exposed and DAA-unexposed patients

Among 334 matched patients, the median follow-up was 27 [IQR: 16.5–39] months in DAA-unexposed patients and 29 [IQR: 17–51.1] months in DAA-exposed patients. Forty-five patients died during the follow-up, 13 DAA-exposed and 32 DAA-unexposed patients. The overall survival rate per 100PY (95%CI) in DAA-exposed patients was 3.4 (95%CI: 1.7–6.8) and 6.6 (95%CI: 4.2–10.4) in DAA-unexposed patients [RR=0.51 (95%CI: 0.22 - 1.8); p-value=0.11]. A sensitivity survival analysis using the RMST technique showed a RMST difference (95%CI) of 2.8 (95CI: -1.7 to 7.3) months, p=0.22. RMST (95%CI) values for the DAA-exposed and the DAA-unexposed were, respectively, 58.1 (95%CI: 55.5 – 60.65) and 55.3 (95%CI: 51.5 -59.0) months.

DISCUSSION

Meta-analysis of individual data involving all studies reported represents the best assessment to be in place in the absence of a randomized prospective trial. Unfortunately, even this MIPD of 977 DAA-exposed patients does not allow to deliver a conclusive message about the increase or decrease of the rate of HCC recurrence associated with the treatment of HCV with DAAs. Our evaluation disclosed a very high heterogeneity of the data source and this prevents any robust message. Studies suffer from the heterogeneity of the patients recruited, the length of follow-up time and strategy and time interval to detect and register recurrence. Thus, despite collecting almost 1000 patients around the world, we were deceived not to be able to provide clarity into the

controversy. However, these data offered relevant information about the clinical profile that may be associated with a higher recurrence risk and that should be carefully assessed in clinical practice in order to decide whether to treat HCV or not. Also, such parameters should be considered when new cohort studies are designed or reported. As detailed in the results, some of the parameters linked to a higher risk (such as increased AFP, tumour burden and multifocality) are not unexpected. A reduced sample size limits the predictive value of prior treatment with chemoembolization, but it may also be a surrogate of the higher tumour burden. Indeed, it has to be retained that the assessment of complete response by imaging after TACE may incur in overestimation and may miss viable tumour cells that will retain the risk of dissemination and recurrence. However, the role of impaired ECOG-PS meaning cancer-related symptoms is not usually included at the time of selecting variables for the predictive models. Indeed, it could be considered also as a surrogate of tumour burden as early HCC tends to be subclinical, while a more advanced tumour stage may be associated with symptoms. Old surgical series already included symptoms as a predictor of poorer survival despite similar tumour stage[2,41,42].

One relevant aspect is the finding of a significant interaction between the absence of DAA-induced SVR and history of recurrence before DAAs. The rate of SVR is somewhat lower in patients with HCC through a not well known mechanism[43]. Thus, failure to achieve SVR when using antiviral agents with high effectiveness may reflect the existence of subclinical malignant clones[44] that are involved in the mechanism of treatment failure.

Finally, the identification of history of recurrence as a predictor of higher risk confirmed prior studies[2,36,45] and is not unexpected. Recurrence reflects malignant spread and even if successful treatment has been in place, the emergence of new sites is highly likely. To avoid such confounder, we assessed if the strength of the data and homogeneity would increase if we excluded patients with prior recurrence. Unfortunately, the expectation was not fulfilled, and the model did not improve. Similar results were obtained when running different statistical models and also when stratifying

patients according to time elapsed between HCC treatment and DAA initiation. This latter aspect is critical as it challenges the proposals to wait to start DAAs for some months after HCC treatment in order to avoid increasing the risk of early recurrence.

Unlike the present MIPD, all the five previously published meta-analyses on aggregate data failed to explain the high level of variability in the risk of HCC recurrence and were unable to identify differences in baseline patients' characteristics that were significantly associated with the probability of HCC recurrence. The results of these meta-analyses of aggregate data may be affected by ecological bias. When a significant heterogeneity of baseline risk of HCC recurrence exists, more accurate treatment comparisons could be achieved only by a MIPD. Finally, the unavailability of individual data hampers the analysis of HCC recurrence as a time-dependent variable. It is recognized that the results of meta-analyses of time-to-event outcomes may be affected by censoring and by the duration of follow-up of individual studies. These limitations are particularly important when the follow-up duration across studies is heterogeneous.

The results of this MIPD are subjected to several limitations. First, we underline the potential limitation of the generalizability of these results to new populations and settings, particularly in patients with more advanced liver disease or more advanced HCC stage. However, the observational studies included in this MIPD were performed by individual data of patients treated in the real-world setting. Therefore, we are confident that clinicians could replicate these results in conventional clinical practice. Second, our primary endpoint was a radiology-based outcome and none of the studies blindly assessed HCC recurrence. Third, the accuracy of our MIPD could have been limited by the high level of clinical and statistical heterogeneity. However, we tried to control for these differences by using a random-effects model including the centre as a covariate. Fourth, lack of data on other potentially relevant risk factors for HCC recurrence, such as microscopic vascular invasion, histology grade, cancer and patient genomic portrait, may have affected our results.

The deceiving results of the MIPD prompted us to develop a collateral assessment through the use of the ITA.LI.CA. database[17]. We were able to compare the rate of HCC recurrence in our multicentre cohort of 977 DAA-exposed patients after successful treatment of HCC with a cohort of 328 DAA-unexposed patients that were matched through a propensity score (167 pairs). Such analysis exposed that the recurrence rate after DAA treatment in patients with early HCC stages was still high and not different from the rate in patients without DAA treatment. The risk is heterogeneous according to the baseline patients' profile, but it remains high. Nevertheless, the overall survival rate in such 167 pairs of patients did not show significant differences in mean survival (58.1 vs 55.3 in DAA-exposed and unexposed patients, respectively), which is a reflection of the complexity of the competing risk analysis in the setting of liver cancer. Unfortunately, the selected studies included in the study did not have data about cirrhosis complications to define the proportion of patients who improves/worse liver function and time-frame between DAA and liver function improvement/deterioration in each group and if it was related to HCV eradication in decompensated patients.

It is important to underline that the large multicentre studies by Singal et al[8,9] included only patients from United States (US), while the present study evaluated patients enrolled around the world (56.1% in Europe, 29.9% in Asia, 11% in Africa and 3% in North America). Therefore, these data may be more generalizable to cohorts across the globe given differences in HCC practice patterns. There may be differences in timing of DAA therapy after curative treatment receipt, availability of liver transplantation as destination therapy, and differences in surveillance utilization. Further, ~~and in that studies~~ nearly half of patients in ~~that the U.S. study cohort~~ had complete response from ~~TACE, TARE, SBRT~~ locoregional therapy, raising increased concern about misclassification of complete response, whereas most patients in our analysis had complete response from traditional curative therapies, such as local ablation or resection. Thus, our analysis

could be useful to well describe the impact of DAAs at international level in patients with early HCC stage.

In summary, the results of our MIPD have shown that the comparison between different cohorts of distinct groups will not allow a valid assessment of outcomes as the heterogeneity exceeds any acceptable cut-off. This currently prevents the end of the controversy about the impact of DAA therapy on the risk of cancer progression in patients successfully treated for this neoplasm. However, at the same time we have shown that the risk of recurrence is 20/100PY in the whole population and 13.7/100PY in the subgroup of patients with the lowest clinical risk. Therefore, the risk of DAA-treated patients is not significantly different from that of untreated HCV patients, at least during the first two years. Longer follow-up studies should define if the recurrence risk is modified or not beyond this time limit and also confirm the finding observed in the survival analysis. Thus, active surveillance is fully justified in this population for whom no effective adjuvant treatment is available. Trials are ongoing in this realm and the current identified predictive factors for recurrence we have identified in the so-called real world provide relevant information to characterize patients included in such investigations.

FIGURE LEGEND

Figure 1. Flow chart of included patients in meta-analysis.

Figure 2. Forest plot of pooled effect for HCC recurrence per 100PY. Lines represent the 95%CI for HCC recurrence rate per 100PY of each study. Size of squares represent the weight of each study. Diamond represents the pooled effect.

Figure 3. Forest plot of pooled effect for Exitus per 100PY. Lines represent the 95%CI for HCC Exitus rate per 100PY of each study. Size of squares represent the weight of each study. Diamond represents the pooled effect.

CONFLICT OF INTEREST

- Víctor Sapena: Travel funding from Bayer.
- Marco Enea: Nothing to disclose
- Ferran Torres: DSMB fees from Basilea Pharmaceutica International and ROVI; educational fees from Janssen and Ferrer.
- Ciro Celsa: Nothing to disclose.
- Giacomo Emanuele Maria Rizzo: Nothing to disclose.
- Pierre Nahon: Consults for Abbvie, AstraZeneca, Bayer, BMS, Eisai, Gilead, Ipsen, Roche. He received grants from Abbvie and BMS.
- Zoe Mariño: speaker fees and consultancy for Gilead and Abbvie.
- Ryosuke Tateishi: Personal fees from Merk Sharp & Dorme, Giliad Sciences and Abbvie GK.
- Tatsuya Minami: Personal fees from Merk Sharp & Dorme, Giliad Sciences and Abbvie GK.
- Angelo Sangiovanni: Noting to disclose.
- Xavier Forns: Consultancy fees for Abbvie and Gilead Sciences.
- Hidenori Toyoda: Speaker fees from AbbVie, Gildead, MSD, and Bayer.
- Stefano Brillanti: Consultancy fees and educational grants from: Gilead Sciences, MSD, Intercept.
- Fabio Conti: Nothing to disclose.

- Elisabetta Degasperi: Advisory Board from AbbVie; Speaking and teaching from Gilead, MSD, AbbVie.
- Ming-Lung Yu: Research grant from Abbott, BMS, Gilead and Merck; Consultant of Abbvie, Abbott, BMS, Gilead, Merck and Roche; Speaker of Abbvie, Abbott, BMS, Gilead, and Merck.
- Pei-Chien Tsai: Nothing to disclose.
- Kevin Jean: Nothing to disclose.
- Mohamed El Kassas: Nothing to disclose.
- Hend I. Shousha: Nothing to disclose.
- Ashraf O. Abdelaziz: Nothing to disclose.
- Claudio Zavaglia: Nothing to disclose.
- Hiroko Nagata: Nothing to disclose.
- Mina Nakagawa: Nothing to disclose.
- Yasuhiro Asahina: Donation-funded department funded by Toray Industries Inc., Gilead Sciences, AbbVie GK and Fuji Rebio Inc.
- Amit Singal: Has received research funding from Abbvie and Gilead. He has served as a consultant for Wako Diagnostics, Glycotest, Exact Sciences, Roche, GRAIL, Genentech, Bayer, Eisai, Exelixis, AstraZeneca, BMS, and TARGET Pharmsolutions.
- Caitlin C. Murphy: Nothing to disclose.
- Mohamed Kohla: Lecture fees from Abbott and Astra Zeneca.
- Chiara Masetti: Nothing to disclose.
- Jean-François Dufour: Advisory committees: Abbvie, Bayer, Bristol-Myers Squibb, Falk, Genfit, Genkyotex, Gilead Sciences, HepaRegenix, Intercept, Lilly, Merck, Novartis. Speaking and teaching: Bayer, Bristol-Myers Squibb, Intercept, Genfit, Gilead Sciences, Novartis, Roche.

- Nicolás Merchante: Research founding, lecture fees, advisory comittes and travel grants from MSD. Lecture fees, Advisory comittes and travel grants from Abbvie and Gilead.
- Luisa Cavalletto: Nothing to disclose.
- Liliana Chemello: Nothing to disclose.
- Stanislas Pol: consulting and lecturing fees from Janssen, Gilead, MSD, Abbvie, Biotest, Shinogui, Viiv and grants from Bristol-Myers Squibb, Gilead, Roche and MSD, without relation to this manuscript.
- Javier Crespo: Grants and research support from Gilead Sciences, AbbVie, MSD, Shionogi, and Intercept Pharmaceuticals (all outside the submitted work). Is a speaker for Gilead Sciences and AbbVie.
- José Luis Calleja: reports grant support and / or consultancy and lecture fees from AbbVie, Gilead Sciences, Bristol-Myers Squibb, Janssen, and MSD.
- Rosanna Villani: research grant from Abbvie.
- Gaetano Serviddio: Consultancy fees and lecture fees from Gilead and Abbvie.
- Alberto Zanetto: Nothing to disclose.
- Sarah Shalaby: Nothing to disclose.
- Francesco Paolo Russo: lecture fees AbbVie, Gilead, MSD, Biotest; travel funds AbbVie, Biotest, Kedrion; research funds AbbVie, Gilead, MSD.
- Rob Bielen: Research grants from MSD, Abbvie and Gilead.
- Jose Ríos: Educational grants from AMGEN, GRÜNENTHAL PHARMA, BOEHRINGER INGELHEIM ESPAÑA, Janssen-Cilag, Ferrer International, Lilly, MERCK SHARP & DOHME and Roche Farma.
- Fanco Trevisani: Consultancy fees from AstraZeneca, Bayer, BMS, Eisai and Sirtex. Lecture fees from AlfaSigma and Bayer. Research grants from Bayer.

- Calogero Cammà: Consultancy fees from Bayer, Eisai, MSD, GILEAD, ABV.
- Jordi Bruix: Consultancy fees from Arqule, Bayer, Novartis, BMS, BTG- Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance/Onxeo, Roche, AbbVie, Merck, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano. Research grants from Bayer and BTG. Educational grants from Bayer and BTG. Lecture fees from Bayer, BTG-Biocompatibles, Eisai, Terumo, Sirtex, Ipsen.
- Giuseppe Cabibbo: Consultancy fees from Bayer, Ipsen.
- María Reig: Consultancy fees from Bayer, BMS, Roche, Ipsen, AstraZeneca and Lilly. Lecture fees from Bayer, BMS, Gilead, Lilly and Roche. Research grants from Bayer and Ipsen.

FINANCIAL SUPPORT

no commercial interest, financial source or material support to disclose.

AUTHOR CONTRIBUTIONS

Conceptualization: MR, FT, CC, GC, JB

Investigation: VS, MR, CC, GC, JB, VS, FT, All collaborators.

Supervision: MR, JB, FT, CC, GC

Statistical Analysis: VS, FT, JR, ME

Writing – original draft: VS, GC, MR

Writing – review & editing: MR, JB, CC

Approval of the version of the manuscript to be published: MR, GC.

REFERENCES

- 1 Reig M, Mariño Z, Perelló C, *et al.* Unexpected high rate of early tumor recurrence in

- patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol* 2016;**65**:95–7. doi:10.1016/j.jhep.2016.04.008
- 2 Cabibbo G, Petta S, Calvaruso V, *et al.* Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. *Aliment Pharmacol Ther* 2017;**46**:688–95. doi:10.1111/apt.14256
 - 3 Waziry R, Hajarizadeh B, Grebely J, *et al.* Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. *J Hepatol* 2017;**67**:1204–12. doi:10.1016/j.jhep.2017.07.025
 - 4 Saraiya N, Yopp AC, Rich NE, *et al.* Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. *Aliment Pharmacol Ther* 2018;**48**:127–37. doi:10.1111/apt.14823
 - 5 Manthravadi S, Paleti S, Pandya P. Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. *Int J Cancer* 2017;**140**:1042–9. doi:10.1002/ijc.30521
 - 6 Singh S, Nautiyal A, Loke YK. Oral direct-Acting antivirals and the incidence or recurrence of hepatocellular carcinoma: A systematic review and meta-Analysis. *Frontline Gastroenterol* 2018;**9**:262–70. doi:10.1136/flgastro-2018-101017
 - 7 Huang P, Liu M, Zang F, *et al.* The development of hepatocellular carcinoma in HCV infected patients treated with DAA: A comprehensive analysis. *Carcinogenesis* 2018;**39**:1497–505. doi:10.1093/carcin/bgy099
 - 8 Singal AG, Rich NE, Mehta N, *et al.* Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. *Gastroenterology* 2019;**157**:1253–63. doi:10.1053/j.gastro.2019.07.040
 - 9 Singal A, Rich NE, Mehta N, *et al.* Direct Acting Antiviral Therapy is not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Gastroenterology 2019;**156**:1683–92.

- 10 Galle PR, Forner A, Llovet JM, *et al.* EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018;**69**:182–236. doi:10.1016/j.jhep.2018.03.019
- 11 Pawlotsky JM, Negro F, Aghemo A, *et al.* EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol* 2018;**69**:461–511. doi:10.1016/j.jhep.2018.03.026
- 12 Ghany MG, Morgan TR. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Hepatology* 2020;**71**:686–721. doi:10.1002/hep.31060
- 13 Singal AG, Lim JK, Kanwal F, *et al.* AGA Clinical Practice Update on Interaction between Oral Direct- Acting Antivirals (DAAs) for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. *Gastroenterology* 2019;**156**:2149–57. doi:10.1053/j.gastro.2019.02.046.AGA
- 14 Marrero JA, Kulik LM, Sirlin CB, *et al.* Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018;**68**:723–50. doi:10.1002/hep.29913
- 15 Cabibbo G, Celsa C, Calvaruso V, *et al.* Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. *J Hepatol* 2019;**71**:265–73. doi:10.1016/j.jhep.2019.03.027
- 16 Moher D, Shamseer L, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;**4**:1–9. doi:10.1186/2046-4053-4-1
- 17 Cabibbo G, Petta S, Barbara M, *et al.* Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. *J Hepatol* 2017;**67**:65–71. doi:10.1016/j.jhep.2017.01.033

- 18 Higgins JPT, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–60. doi:10.1136/bmj.327.7414.557
- 19 Torres F, Ríos J, Saez-Peñataro J, *et al.* Is Propensity Score Analysis a Valid Surrogate of Randomization for the Avoidance of Allocation Bias? *Semin Liver Dis* 2017;**37**:275–86. doi:10.1055/s-0037-1606213
- 20 Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. *Stat Med* 2008;**27**:2037–49. doi:10.1002/sim.3150
- 21 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009;**28**:3083–107. doi:10.1002/sim
- 22 Royston P, Parmar MKB. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. *Stat Med* 2011;**30**:2409–21. doi:10.1002/sim.4274
- 23 Kolly P, Waidmann O, Vermehren J, *et al.* Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. *J Hepatol* 2017;**67**:876–8. doi:10.1016/j.jhep.2017.07.007
- 24 Masetti C, Lionetti R, Lupo M, *et al.* Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis. *J Hepatol* 2018;**68**:S533. doi:10.1016/s0168-8278(18)31319-9
- 25 Merchante N, Rodríguez-Arrondo F, Revollo B, *et al.* Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. *AIDS* 2018;**32**:1423–30. doi:10.1097/QAD.0000000000001809
- 26 Minami T, Tateishi R, Nakagomi R, *et al.* The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular

- carcinoma. *J Hepatol* 2016;**65**:1272–3. doi:10.1016/j.jhep.2016.07.043
- 27 Nagata H, Nakagawa M, Asahina Y, *et al.* Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. *J Hepatol* 2017;**67**:933–9. doi:10.1016/j.jhep.2017.05.028
- 28 HEPADAT - Hepatocarcinoma After DAA, Treatment. IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multi- center prospective trial in Italy. *Hepatol - AASLD Abstr* 2017;**66**:734–5.
- 29 Toyoda H, Kumada T, Tada T, *et al.* Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. *Aliment Pharmacol Ther* 2018;**48**:664–70.
doi:10.1111/apt.14914
- 30 Tsai PC, Huang CF, Yu ML. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy. *J Hepatol* 2017;**66**:464.
doi:10.1016/j.jhep.2016.10.035
- 31 Villani R, Facciorusso A, Bellanti F, *et al.* DAAs increase serum VEGF level: a rationale for tumour risk recurrence during anti-HCV treatment. *J Hepatol* 2017;**66**:S735.
doi:10.1016/s0168-8278(17)31959-1
- 32 Abdelaziz AO, Nabil MM, Abdelmaksoud AH, *et al.* De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus. *Eur J Gastroenterol Hepatol* 2018;**30**:1–5. doi:10.1097/MEG.0000000000001004
- 33 Zavaglia C, Okolicsanyi S, Cesarini L, *et al.* Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? *J Hepatol* 2017;**66**:236–7. doi:10.1016/j.jhep.2016.08.016
- 34 The ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an

- effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. *J Hepatol* 2016;**65**:734–40. doi:10.1016/j.jhep.2016.05.045
- 35 Calleja JL, Crespo J, Rincón D, *et al.* Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. *J Hepatol* 2017;**66**:1138–48. doi:10.1016/j.jhep.2017.01.028
- 36 Cavalletto L, Aliberti C, Romano A, *et al.* Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer. *J Hepatol* 2017;**66**:S536. doi:10.1016/s0168-8278(17)31475-7
- 37 Conti F, Buonfiglioli F, Scuteri A, *et al.* Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J Hepatol* 2016;**65**:727–33. doi:10.1016/j.jhep.2016.06.015
- 38 Degasperi E, D’Ambrosio R, Iavarone M, *et al.* Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. *Clin Gastroenterol Hepatol* 2019;**17**:1183-1191.e7. doi:10.1016/j.cgh.2018.10.038
- 39 El Kassas M, Funk AL, Salaheldin M, *et al.* Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis. *J Viral Hepat* 2018;**25**:623–30. doi:10.1111/jvh.12854
- 40 Kohla M, Omar Y, Assem M, *et al.* Early recurrence of hepatocellular after successful therapy with Direct Acting Antiviral Agents for chronic hepatitis C: An observational study. *ILCA Annu Conf* 2017 2017;:47.
- 41 Tang ZY, Wu MC, S.S X. *Primary Liver Cancer*. China Academic Publishers 1989.
- 42 Tang ZY. *Subclinical Hepatocellular Carcinoma*. China Academic Publishers 1985.
- 43 Prenner SB, VanWagner LB, Flamm SL, *et al.* Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. *J Hepatol*

2017;**66**:1173–81. doi:10.1016/j.jhep.2017.01.020

- 44 Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: An awakening field. *Nat Rev Cancer* 2014;**14**:611–22. doi:10.1038/nrc3793
- 45 Nishibatake Kinoshita M, Minami T, Tateishi R, *et al.* Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. *J Hepatol* 2019;**70**:78–86. doi:10.1016/j.jhep.2018.09.029

